Abstract: There is disclosed a complex comprised of an insoluble polymer carrier to which monomeric human albumin is covalently bound and of a pre-S hepatitis B surface antigen bound in an elutable form to the monomeric human albumin by its pre-S(2)- and/or pre-S(1)-region. This complex may be used for therapeutic and diagnostic purposes and enables the rapid and efficient purification of pre-S-HBsAg by affinity chromatography.

Abstract: To produce activated protein C, protein C is treated with plasmin. Activation is effected in a quick and simple manner. Contamination of the activated protein C with thrombin is avoided.

Abstract: In order to avoid the risk of undesired side reactions of blood products, the latter are produced from plasma by using chymotrypsin to inactivate prekallikrein activator. These preparations are obtained by the fractionated enrichment of plasma proteins, with the proviso that a chymotrypsin solution or immobilized chymotrypsin is added to the fractions at any stage of the fractionation process. Before completion of the preparations, the chymotrypsin or the immobilized trypsin is removed from the preparations.

Abstract: Vaccines that are active against Pseudomonas aeruginosa infections contain a single flagellar (H) antigen of serotype a or a combination of a single flagellar (H) antigen of serotype a with a flagellar (H) antigen of serotype b. Applied to man, the vaccines according to the invention induce the formation of antibodies that are directed against any combination of partial flagellar (H) antigens a.sub.0, a.sub.1, a.sub.2, a.sub.3, a.sub.4 and b, inhibiting the motility of Pseudomonas aeruginosa pathogens and inducing the killing of the pathogens by phagocytizing cells of the human immune system.

Abstract: There is disclosed a pharmaceutical preparation based on Lys-plasminogen and available in the lyophilized form. This preparation contains a serine-protease inhibitor and optionally an inhibitor co-factor, preferably in an amount of 0.5 to 30 nmol per mg Lys-plasminogen. This preparation is free of side-effects and may be used for the treatment and prophylaxis of plasminogen deficiency syndromes and thromboses as well as for the production of thromboresistant artificial organs.

Abstract: Factor IX is selectively adsorbed by means of hydrophobic chromatography from an aqueous mixture containing at least one plasma zymogen or a vitamin-K dependent protein in addition to factor IX. By this method, the efficient enrichment of factor IX for the production of pharmaceutical preparations has become possible.

Abstract: A preparation for the treatment and prevention of thromboses and thromboembolic complications is disclosed, which preparation has a content of protein S at a concentration at least 50 times that present in native plasma and is free from C4b-binding protein, optionally in combination with a content of activated protein C.

Abstract: Preparations active against Pseudomonas aeruginosa infections, namely vaccines for active immunization as well as preparations containing antibodies and destined for passive protection; as well as methods for the production thereof.The vaccines contain protective flagellar (H) antigens of the serotype a and b, which consist of monomeric components, each monomeric component is composed of certain amino acids having a certain N-terminal amino acid sequence and has a certain molecular weight. The vaccines are made from purified flagellar (H) antigen solutions. The immunoglobulin-G-containing preparations contain flagellar (H) antibodies obtained from the blood plasma of human donors or mammals immunized with protective flagellar (H) antigens. They can be purified by methods of affinity chromatography.

Abstract: There is disclosed a method of determining the presence of incompatibility-reaction-causing substances in blood products. There is also disclosed a method of inactivating incompatibility-reaction-causing substances in blood products to be applied therapeutically and prophylactically. For this purpose, a fraction obtained from human or animal blood is treated with pancreas enzymes bound to water insoluble carrier material and, optionally, the fraction is subjected to further fractionation and concentration.

Abstract: A preparation for the treatment and prevention of thromboses and thromboembolic complications is disclosed, which preparation has a content of protein S at a concentration at least 50 times that present in native plasma and is free from C4b-binding protein, optionally in combination with a content of activated protein C.

Abstract: There is disclosed a biologic absorbable implant material for filling and closing soft-tissue cavities and for replacing soft-tissue parts, and a method of its preparation. The implant material consists essentially of bone tissue of human or animal origin, is decalcified, and the original protein content of the osseous hard substance is unchanged. By cross-linking of these native proteins with a cross-linking agent, a high elasticity, a good stability and a marked memory-effect are attained. The method for the preparation of the implant material includes degreasing, decalcification and cross-linking of the available proteins and then drying and sterilizing of the material.

Abstract: An immunoglobulin-G-containing fraction from human or animal plasma comprising monomeric IgG molecules as well as at least 70% gammaglobulins, destined for intravenous application.The fraction has a low anticomplementary activity and is substantially free of vasoactive and leucopenically active as well as bronchospastic substances.

Abstract: This invention relates to a method for releasing cell cultures from microcarriers in which a trypsin solution is directed through a container with the microcarriers therein in a flow-through process. The released cells are immediately withdrawn from the carrier, with the trypsin solution being inactivated and/or removed after leaving the container.

Abstract: In order to avoid the risk of undesired side reactions of blood products, the latter are produced from plasma by using chymotrypsin to inactivate prekallikrein activator. These preparations are obtained by the fractionated enrichment of plasma proteins, with the proviso that a chymotrypsin solution or immobilized chymotrypsin is added to the fractions at any stage of the fractionation process. Before completion of the preparations, the chymotrypsin or the immobilized trypsin is removed from the preparations.

Abstract: A cage structure for restraining primates includes a bottom of rectangular ground plan and formed by rods or tubes, side walls surrounding the bottom, and a ceiling. A cage structure of this type is to be manufacturable in any desired size and at low an expenditure as possible. The cage develops only low levels of noise. To this end, only one of the side walls, i.e., the front wall, is formed by rods or tubes, while the remaining three side walls and the ceiling are made of concrete or brickwork having their interior surfaces smoothed. The wall opposite the front wall, i.e., the rear wall, is displaceable towards and away from the front wall. At least one side wall and the ceiling incorporate inspection panes made of bullet-proof glass.

Abstract: Preparations active against Pseudomonas aeruginosa Infections, namely vaccines for active immunization as well as preparations containing antibodies and destined for passive protection; as well as methods for the production thereof.The vaccines contain protective flagellar (H) antigens of the serotype a and b, which consist of monomeric components, each monomeric component is composed of certain amino acids having a certain N-terminal amino acid sequence and has a certain molecular weight. The vaccines are made from purified flagellar (H) antigen solutions. The immunoglobulin-G-containing preparations contain flagellar (H) antibodies obtained from the blood plasma of human donors or mammals immunized with protective flagellar (H) antigens. They can be purified by methods of affinity chromatography.

Abstract: A fermenter for culturing cell cultures, and particularly on microcarriers. The fermenter comprises a vessel in which the cell cultures are maintained in suspension by means of an agitator. A screen aerator supplies oxygen in finely distributed form to the suspension at a distance away from the rotating axis of the agitator.

Abstract: A tissue adhesive in lyophilized form contains at least one biologically compatible tenside beside fibrinogen and factor XIII and optionally further proteins as well as adjuvants or additives. The presence of these biologically compatible tensides was found to shorten the reconstitution times of lyophilized tissue adhesive preparations without negatively affecting the biochemical, mechanical or biological properties of the preparation or of the tibrin formed therefrom.

Abstract: There is disclosed a method of inactivating reproducible filterable pathogens in blood plasma products by applying elevated temperatures. The blood plasma products are heat treated in a solid state in a closed inactivation container in the presence of specific amounts of water and organic compounds, provided that the water substantially remains physically bound to the blood plasma products, while the organic compound is present in a gaseous form in the atmosphere. The water content of the blood plasma products is 0.08 to 0.40. The concentration of the organic compounds in the gaseous phase is 0.01 to 10 g per liter of container volume.

Abstract: There is disclosed a method of determining the presence of incompatibility-reaction-causing substances in blood products. There is also disclosed a method of inactivating incompatibility-reaction-causing substances in blood products to be applied therapeutically and prophylactically. For this purpose, a fraction obtained from human or animal blood is treated with pancreas enzymes bound to water insoluble carrier material and, optionally, the fraction is subjected to further fractionation and concentration.